Article Text

Download PDFPDF
Survival After Second-Line Intraperitoneal Therapy for the Treatment of Epithelial Ovarian Cancer: The Gynecologic Oncology Group Experience
  1. Maurie Markman, MD*,
  2. Mark Brady, PhD,
  3. Alan Hutson, PhD and
  4. Jonathan S. Berek, MD
  1. * University of Texas, MD Anderson Cancer Center, Houston, TX;
  2. Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; and
  3. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford Cancer Center, Stanford, CA.
  1. Address correspondence and reprint requests to Maurie Markman, University of Texas, MD Anderson, 1515 Holcombe Blvd, Mail Box 121, Houston, TX 77030-4009. Email: MMarkman{at}


Objective: To assess the association between patient-disease characteristics and overall survival (OS) after second-line intraperitoneal (IP) treatment of ovarian cancer.

Methods: Data were aggregated from 7 Gynecologic Oncology Group (GOG) phase 2 studies conducted between 1988 and 1995 to evaluate IP therapy for partially responsive or recurrent disease but no tumor masses greater than 0.5 cm. Factors evaluated include age, performance status, extent of residual disease, tumor grade, and histologic diagnosis.

Results: A total of 432 eligible women were treated on 1 of the 7 second-line phase 2 IP trials. The median OS was 2.4 years (range of individual study medians, 1.9-2.9 years). Relative to women with grade 1 cancers, those with grade 2 or 3 cancers experienced 1.82 (95% confidence interval [CI], 1.21-2.74) and 2.02 (95% CI, 1.35-3.03) times greater instantaneous death rates, respectively, and those with clear cell adenocarcinoma experienced death rates 6.00 (95% CI, 3.27-10.9) times greater. The extent of residual disease, surgically assessed before starting study treatment, was also associated with OS. Relative to those who had no evidence of gross disease, those with gross disease that was completely resected, or with unresectable disease (not larger than 0.5 cm), experienced death rates 1.74 (95% CI, 1.25-2.42) and 2.26 (95% CI, 1.67-3.05) times greater, respectively.

Conclusions: There are patient and disease characteristics strongly associated with survival after second-line IP treatments. These factors are relevant to clinicians considering IP therapy outside the investigative setting and for the development of future studies in this area.

  • Ovarian cancer
  • Intraperitoneal chemotherapy
  • Cisplatin
  • Paclitaxel

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.